Prova Education: Changing the Practice of Medicine

Changing the Practice of Medicine

Discover CME, tools, and guideline-focused education to
improve your knowledge - and patient outcomes.

From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
CME/CE
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
0.25 credits
- María-Victoria Mateos, MD, PhD
- Luciano Costa, M.D., Ph.D.
0.25 credits
Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events
Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events
MinuteCE®
Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events
0.75 program credits
- Eileen M. O'Reilly, MD
- Kathryn Arbour
0.75 program credits
RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
MinuteCE®
RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
0.75 program credits
- Kathryn Arbour
- Eileen M. O'Reilly, MD
0.75 program credits
Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors 
Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors 
MinuteCE®
Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors 
0.75 program credits
- Eileen M. O'Reilly, MD
0.75 program credits
Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
MinuteCE®
Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
0.75 program credits
- Kathryn Arbour
- Eileen M. O'Reilly, MD
0.75 program credits
Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
MinuteCE®
Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
0.75 program credits
- Kathryn Arbour
- Eileen M. O'Reilly, MD
0.75 program credits
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
MinuteCE®
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
0.75 program credits
- Kathryn Arbour
0.75 program credits
Breaking the Line: Moving Bispecific Antibodies Upstream in Treating Multiple Myeloma
Breaking the Line: Moving Bispecific Antibodies Upstream in Treating Multiple Myeloma
CME/CE
Breaking the Line: Moving Bispecific Antibodies Upstream in Treating Multiple Myeloma
0.25 credits
- María-Victoria Mateos, MD, PhD
0.25 credits

CME/CE

Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
CME/CE
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
0.50 credits
- Kevin J Harrington, PhD, FRCP, FRCR, FRSB
- Cristina Rodriguez, MD
0.50 credits
MinuteCE®
The New Era of RAS Targeting: Mechanisms, Evidence, and Clinical Integration of ON-State Inhibitors
0.75 credits 8 episodes
- Kathryn Arbour
- Eileen M. O'Reilly, MD
0.75 credits 8 episodes
Severity Assessment: Can You Pin the Stage on the Patient?
Severity Assessment: Can You Pin the Stage on the Patient?
MinuteCE®
Severity Assessment: Can You Pin the Stage on the Patient?
1.00 program credit
- Jennifer Geremia, PA-C
- Brooke Hodnick, PA-C, MPAS
1.00 program credit
Case Review: Can You Crack This IBD Case? 
Case Review: Can You Crack This IBD Case? 
MinuteCE®
Case Review: Can You Crack This IBD Case? 
1.00 program credit
- David Rubin, MD
- Kimberly D. Orleck, PA-C
1.00 program credit
IBD Immunopathogenesis: Do You Know What You're Blocking?
IBD Immunopathogenesis: Do You Know What You're Blocking?
MinuteCE®
IBD Immunopathogenesis: Do You Know What You're Blocking?
1.00 program credit
- Kimberly D. Orleck, PA-C
- Brooke Hodnick, PA-C, MPAS
1.00 program credit
Diagnosing IBD: Is It IBD or Something Else? Can You Tell?  
Diagnosing IBD: Is It IBD or Something Else? Can You Tell?  
MinuteCE®
Diagnosing IBD: Is It IBD or Something Else? Can You Tell?  
1.00 program credit
- Kimberly D. Orleck, PA-C
- Jennifer Geremia, PA-C
1.00 program credit

Clinical Practice

Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
MinuteCE®
Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
0.75 program credits
- Kathryn Arbour
- Eileen M. O'Reilly, MD
0.75 program credits
Frontline Insights: Emerging Therapeutic Strategies in HNSCC
Frontline Insights: Emerging Therapeutic Strategies in HNSCC
CME/CE
Frontline Insights: Emerging Therapeutic Strategies in HNSCC
0.25 credits
- Kevin J Harrington, PhD, FRCP, FRCR, FRSB
- Christophe Le Tourneau, MD, PhD
0.25 credits
Tailoring Treatment: Can You Select the Best Therapy? 
Tailoring Treatment: Can You Select the Best Therapy? 
MinuteCE®
Tailoring Treatment: Can You Select the Best Therapy? 
1.00 program credit
- David Rubin, MD
- Brooke Hodnick, PA-C, MPAS
1.00 program credit
Switching Strategies: Switch or Stay—What’s Your Call? 
Switching Strategies: Switch or Stay—What’s Your Call? 
MinuteCE®
Switching Strategies: Switch or Stay—What’s Your Call? 
1.00 program credit
- David Rubin, MD
- Brooke Hodnick, PA-C, MPAS
1.00 program credit
Case Review: Targets Are Met—Can You Stick the Landing? 
Case Review: Targets Are Met—Can You Stick the Landing? 
MinuteCE®
Case Review: Targets Are Met—Can You Stick the Landing? 
1.00 program credit
- David Rubin, MD
- Jennifer Geremia, PA-C
1.00 program credit
The Tumor That’s Not So Tiny: Understanding the Impact of TGCT
The Tumor That’s Not So Tiny: Understanding the Impact of TGCT
MinuteCE®
The Tumor That’s Not So Tiny: Understanding the Impact of TGCT
1.00 program credit
- A.J. Gelderblom, MD, PhD
1.00 program credit

Programs

Remission: Can You Prove It? 
Remission: Can You Prove It? 
MinuteCE®
Remission: Can You Prove It? 
1.00 program credit
- David Rubin, MD
- Kimberly D. Orleck, PA-C
1.00 program credit
Treat-to-Target: Are We There Yet? 
Treat-to-Target: Are We There Yet? 
MinuteCE®
Treat-to-Target: Are We There Yet? 
1.00 program credit
- Kimberly D. Orleck, PA-C
- Jennifer Geremia, PA-C
1.00 program credit
Implementing the Latest Diagnostic and Treatment Approaches for Generalized Myasthenia Gravis
Implementing the Latest Diagnostic and Treatment Approaches for Generalized Myasthenia Gravis
CME/CE
Implementing the Latest Diagnostic and Treatment Approaches for Generalized Myasthenia Gravis
0.50 credits
- Pushpa Narayanaswami, MD, FAAN
0.50 credits
Unlocking the CSF1R Code: Targeted Pathways and Tailored Choices
Unlocking the CSF1R Code: Targeted Pathways and Tailored Choices
MinuteCE®
Unlocking the CSF1R Code: Targeted Pathways and Tailored Choices
1.00 program credit
- A.J. Gelderblom, MD, PhD
1.00 program credit
Beyond the Scalpel: When TGCT Surgery Isn’t the Solution
Beyond the Scalpel: When TGCT Surgery Isn’t the Solution
MinuteCE®
Beyond the Scalpel: When TGCT Surgery Isn’t the Solution
1.00 program credit
- Michiel van de Sande, MD, PhD
1.00 program credit
Clinical Evidence in Focus: Interpreting Data on Systemic Therapy Targeting CSF1R
Clinical Evidence in Focus: Interpreting Data on Systemic Therapy Targeting CSF1R
MinuteCE®
Clinical Evidence in Focus: Interpreting Data on Systemic Therapy Targeting CSF1R
1.00 program credit
- A.J. Gelderblom, MD, PhD
1.00 program credit

Changing the Practice of Medicine

Popular

CME/CE

Clinical Practice

Programs

Title

Share on ReachMD